Safety of secukinumab for axial spondyloarthritis in Indian adults
Part of Bones, joints & muscles clinical trials.
This study tests the safety of a drug called secukinumab (given as an injection under the skin) for people with axial spondyloarthritis, a type of arthritis that affects the spine and joints. It aims to see if this treatment is safe for adults in India with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of axial spondyloarthritis (including ankylosing spondylitis or non-radiographic axial spondyloarthritis).
- You must be willing to provide written consent to participate.
- You cannot be pregnant or breastfeeding.
- You cannot have any medical condition that makes it unsafe for you to take the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two biologic medications (adalimumab and secukinumab) can better relieve symptoms of ankylosing spondylitis, a type of arthritis that affects the spine. It may help if you have not responded well to standard nonsteroidal anti-inflammatory drugs (NSAIDs) and you have active disease.
This study is looking at how well secukinumab works for people with ankylosing spondylitis in Korea who have never taken a biologic or JAK inhibitor before. It aims to understand if the drug helps control symptoms over a short period of time.
This study tracks how axial spondyloarthritis progresses over time in Chinese patients. It helps doctors understand the natural course of the disease and improve care.
This trial tests a new medication called vilamakitug to see if it can reduce pain and inflammation in people with axial spondyloarthritis, a type of arthritis that affects the spine and joints. It may help those who haven't found relief with other treatments.
This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.
This study compares two newer medicines (an IL-17 inhibitor and a JAK inhibitor) for people with axial spondyloarthritis whose previous TNF inhibitor did not work or caused side effects. The goal is to see which one works better for controlling symptoms.
Hear when a new Axial Spondyloarthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.